{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:49:01Z","timestamp":1791618541420,"version":"4.3.4"},"reference-count":52,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Perioperative management in haemophilia often requires on\u2010demand use of clotting factor concentrates (CFC) and\/or bypassing agents. Rebalancing agents (fitusiran, concizumab, marstacimab) offer a novel approach to prophylaxis by modulating endogenous anticoagulant pathways to restore haemostatic balance. While these therapies offer advantages, such as subcutaneous delivery and factor\u2010independent mechanisms, thromboembolic risk and optimal concurrent on\u2010demand CFC\/bypassing agent dosing perioperatively are not understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate available evidence on the efficacy and safety of rebalancing therapies in haemophilia A or B in the perioperative setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review of perioperative use of rebalancing therapies was conducted using targeted searches of PubMed, Scopus, and major international haematology conference abstracts through to December 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Evidence suggests rebalancing therapies may contribute to effective perioperative haemostasis, often with reduced dosing or frequency of CFC or bypassing agents, though data is overall limited. Early studies of fitusiran and concizumab report generally favourable haemostatic outcomes in minor and selected major procedures. Perioperative bleeding events with fitusiran use are reported most often as mild to moderate and haemostasis was rated excellent\/good in 90%\u201395% of cases. Similarly, concizumab data show bleeding events in 39\/94 surgeries, the majority of which were mild to moderate. Data for marstacimab is limited but suggest feasibility with temporary interruption and CFC support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Limited perioperative evidence suggests that rebalancing therapies may contribute to acceptable haemostatic outcomes with reduced use of conventional haemostatic agents in selected settings. However, important clinical uncertainties remain, highlighting the need for further prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.70425","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:06:18Z","timestamp":1791615978000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Management in Persons With Haemophilia on Rebalancing Therapies: A Narrative Review"],"prefix":"10.1111","author":[{"given":"Amanda M.","family":"Henderson","sequence":"first","affiliation":[{"name":"Division of Hematology and Hematological Malignancies, Department of Medicine University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Khalife","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute  Ottawa Ontario Canada"},{"name":"Division of Hematology, Department of Medicine University of Ottawa  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Uminski","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematological Malignancies, Department of Medicine University of Calgary  Calgary Alberta Canada"},{"name":"Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221093"},{"key":"e_1_2_11_3_1","doi-asserted-by":"crossref","unstructured":"A.Srivastava E.Santagostino A.Dougall et\u00a0al. \u201cWFH Guidelines for the Management of Hemophilia \u201dsupplement Haemophilia26 no.S6(2020):1\u2013158 https:\/\/doi.org\/10.1111\/hae.14046.","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.232132"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13877"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000253"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S159297"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001140"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15697"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2025.2519002"},{"key":"e_1_2_11_12_1","unstructured":"C.Negrier J. K.Pasi M.Ragni S. W.Pipe Y.Cue andB. P.Fitusiran An siRNA Therapeutic Targeting Antithrombin for the Treatment of Haemophilia: Proposed Revisions to Dose and Regimen as a Risk Mitigation for Vascular Thrombosis. [abstract] European Association for Haemophilia and Allied Disorders virtual meeting (2021) https:\/\/scholar\u2010google\u2010com.ezproxy.lib.ucalgary.ca\/scholar_lookup?title=Fitusiran%2C%20an%20siRNA%20therapeutic%20targeting%20antithrombin%20for%20the%20treatment%20of%20haemophilia%3A%20proposed%20revisions%20to%20dose%20and%20regimen%20as%20a%20risk%20mitigation%20for%20vascular%20thrombosis%20abstract&publication_year=2021&author=C%20Negrier&author=KJ%20Pasi&author=M%20Ragni&author=SW%20Pipe&author=Y%20Cue&author=P%20Bhagunde."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006403"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-139563","article-title":"Risk Mitigation Strategy for Concizumab Clinical Trials After Pause Due to Non\u2010Fatal Thrombotic Events","volume":"136","author":"Seremetis S.","year":"2020","journal-title":"Blood"},{"key":"e_1_2_11_15_1","unstructured":"NBDF and WFH Statement on Severe Adverse Event With Marstacimab Rebalancing Agent for Hemophilia. Accessed September 25 2026.https:\/\/www.bleeding.org\/news\/nbdf\u2010and\u2010wfh\u2010statement\u2010on\u2010severe\u2010adverse\u2010event\u2010with\u2010marstacimab\u2010rebalancing\u2010agent\u2010for\u2010hemophilia."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027468"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.442"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471\u20101842.2009.00848.x"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3233\/WOR\u20102001\u201000173"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616569"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027008"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)00284\u20102"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00037\u20106"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021864"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.10.124"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.2366.2366"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013900"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15270"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2024.09.949"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20104850"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216455"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12864"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010018\u20100922\u20106"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14272"},{"key":"e_1_2_11_37_1","unstructured":"Alhemo (Concizumab\u2010mtci) Injection for Subcutaneous Use. Published Online December 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761315s000lbl.pdf."},{"key":"e_1_2_11_38_1","unstructured":"Alhemo: Summary of Product Characteristics. Published Online January 17 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/alhemo\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_11_39_1","unstructured":"Novo Nordisk Canada Inc.Alhemo (Concizumab Injection) Product Monograph Including Patient Medication Information (March 2023) https:\/\/www.novonordisk.ca\/content\/dam\/nncorp\/ca\/en\/products\/alhemo\u2010en\u2010product\u2010monograph.pdf."},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14479"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010148571"},{"key":"e_1_2_11_42_1","unstructured":"V.Jimenez Yuste I.Fernandez Bello andM.Martin\u2010Salcez \u201cSuccessful Perioperative Hemostasis Use of rFVIIa in Major Orthopedic Surgery in a Severe Hemophilia B Patient With Inhibitors on Concizumab Prophylaxis \u201dsupplement Haemophilia26 no.S2(2020):129."},{"key":"e_1_2_11_43_1","unstructured":"A.Delaney M.Edwards andK.Hampton \u201cSuccessful Laser Refractive Eye Surgery During Treatment With Concizumab in a Patient With Severe Haemophilia A With an Inhibitor \u201dsupplement Haemophilia26 no.S2(2020):49\u201350."},{"key":"e_1_2_11_44_1","unstructured":"A.Mena\u2010Santano F.Lopez\u2010Jaime F.Munoz\u2010Lopez M.Perez\u2010Raya andA.Doblas\u2010Marquez \u201cMinor Surgeries in Patients Receiving Prophylaxis With Concizumab: Experience in Our Center \u201dsupplement Haemophilia28 no.S1(2022):72."},{"key":"e_1_2_11_45_1","unstructured":"F.Lopez\u2010Jaime A.Mena\u2010Santano F.Munoz\u2010Lopez S.Martin\u2010Tellez A.Doblas\u2010Marquez andM.Perez\u2010Raya \u201cPatient Receiving Prophylaxis With Concizumab and Undergoing Minor Surgery: A Case Report \u201dsupplement Haemophilia27 no.S2(2021):103\u2013104."},{"key":"e_1_2_11_46_1","doi-asserted-by":"crossref","unstructured":"A. K.Chan C.Barnes M.Mathias et\u00a0al. \u201cSurgical Procedures and Hemostatic Outcome in Patients With Hemophilia Receiving Concizumab Prophylaxis During the Phase 3 Explorer7 and Explorer8 Trials \u201dsupplement Blood142 no.S1(2023):30\u201330 https:\/\/doi.org\/10.1182\/blood\u20102023\u2010179739.","DOI":"10.1182\/blood-2023-179739"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S500480"},{"key":"e_1_2_11_48_1","unstructured":"European Medicines Agency (EMA).Hympavzi INN\u2010Marstacimab: EPAR \u2013 Product Information. EMA\/464842\/2024. Published Online November 18 2024 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/hympavzi\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_11_49_1","unstructured":"Pfizer Inc.Hympavzi (Marstacimab\u2010hncq) Injection for Subcutaneous Use [Package Insert]. Published Online 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761369s000lbl.pdf."},{"key":"e_1_2_11_50_1","first-page":"4","article-title":"Surgical and Medical Procedures in Participants With Hemophilia A or B Without Inhibitors Receiving Marstacimab in the Basis and Open\u2010Label Extension trials","volume":"31","author":"Benitez O.","year":"2025","journal-title":"Haemophilia"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20103068"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000849"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1614163"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70425","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.70425","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:06:19Z","timestamp":1791615979000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.70425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":52,"alternative-id":["10.1111\/hae.70425"],"URL":"https:\/\/doi.org\/10.1111\/hae.70425","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"2026-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"hae.70425"}}